drugset / Trial / NCT06437353
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
Phase 2
Recruiting
74 enrolled
Anhui Provincial Cancer Hospital
Hutchison Medipharma Limited · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this type of clinical trial study is to evaluate the safety and efficacy of Surufatinib combined with Carboplatin/Paclitaxel and Surufatinib combined with Olaparib as first-line and maintenance therapy for newly diagnosed high-risk ovarian cancer
Timeline
- Start
- 2024-05-25
- Primary completion
- 2025-10-30
- Completion
- 2027-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Olaparib | Small molecule | 300 mg | — |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Surufatinib | Small molecule | 250 mg | — |